Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium PR...
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products PR Newswire INDIANAPOLIS, Oct. 30, 2024 Revenue in Q3 2024 increased 20%, driven by...
U.S. index futures rose slightly in Wednesday’s pre-market as traders assessed Alphabet (NASDAQ:GOOGL)’s strong quarterly results released post-close, while AMD (NASDAQ:AMD) shares dropped...
Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study PR Newswire INDIANAPOLIS, Oct. 29, 2024 A change in the...
Lilly declares fourth-quarter 2024 dividend PR Newswire INDIANAPOLIS, Oct. 28, 2024 INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has...
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease PR...
Philips (NYSE:PHG) – In the third quarter, Philips recorded €4.4 billion in sales, a 2% annual decline, though net income doubled to €181 million, and diluted earnings per share rose from...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.